These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8485565)

  • 1. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE.
    Wallace DJ; Linker-Israeli M; Metzger AL; Stecher VJ
    Lupus; 1993 Feb; 2 Suppl 1():S13-5. PubMed ID: 8485565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of hydroxychloroquine therapy on serum levels of immunoregulatory molecules in patients with systemic lupus erythematosus.
    Wallace DJ; Linker-Israeli M; Hyun S; Klinenberg JR; Stecher V
    J Rheumatol; 1994 Feb; 21(2):375-6. PubMed ID: 8182661
    [No Abstract]   [Full Text] [Related]  

  • 3. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs.
    Rahman P; Gladman DD; Urowitz MB; Yuen K; Hallett D; Bruce IN
    J Rheumatol; 1999 Feb; 26(2):325-30. PubMed ID: 9972966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs.
    López P; Gómez J; Mozo L; Gutiérrez C; Suárez A
    Arthritis Res Ther; 2006; 8(2):R42. PubMed ID: 16507146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of functional interleukin 10/tumor necrosis factor-alpha polymorphisms on interferon-alpha, IL-10, and regulatory T cell population in patients with systemic lupus erythematosus receiving antimalarial treatment.
    López P; Gómez J; Prado C; Gutiérrez C; Suárez A
    J Rheumatol; 2008 Aug; 35(8):1559-66. PubMed ID: 18597405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
    Dejica D
    Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.
    Tektonidou MG; Laskari K; Panagiotakos DB; Moutsopoulos HM
    Arthritis Rheum; 2009 Jan; 61(1):29-36. PubMed ID: 19116963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus.
    Jung H; Bobba R; Su J; Shariati-Sarabi Z; Gladman DD; Urowitz M; Lou W; Fortin PR
    Arthritis Rheum; 2010 Mar; 62(3):863-8. PubMed ID: 20131232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus.
    Parke A; West B
    J Rheumatol; 1996 Oct; 23(10):1715-8. PubMed ID: 8895146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimalarial drugs, systemic lupus erythematosus and pregnancy.
    Parke AL
    J Rheumatol; 1988 Apr; 15(4):607-10. PubMed ID: 3397970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of antimalarials in systemic lupus erythematosus.
    Esdaile JM
    Lupus; 1993 Feb; 2 Suppl 1():S3-8. PubMed ID: 8485568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus.
    Bruce IN
    Rheumatology (Oxford); 2005 Dec; 44(12):1492-502. PubMed ID: 16234277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
    Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
    J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus.
    McLaurin EY; Holliday SL; Williams P; Brey RL
    Neurology; 2005 Jan; 64(2):297-303. PubMed ID: 15668428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking.
    Kreuter A; Gaifullina R; Tigges C; Kirschke J; Altmeyer P; Gambichler T
    Arch Dermatol; 2009 Mar; 145(3):244-8. PubMed ID: 19289751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimalarial drugs, pregnancy and lactation.
    Parke AL
    Lupus; 1993 Feb; 2 Suppl 1():S21-3. PubMed ID: 8485567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
    Toubi E; Kessel A; Rosner I; Rozenbaum M; Paran D; Shoenfeld Y
    Scand J Immunol; 2006 Apr; 63(4):299-303. PubMed ID: 16623930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimalarial agents and lupus.
    Wallace DJ
    Rheum Dis Clin North Am; 1994 Feb; 20(1):243-63. PubMed ID: 8153401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics.
    Omdal R; Mellgren SI; Koldingsnes W; Jacobsen EA; Husby G
    J Rheumatol; 2002 Mar; 29(3):482-6. PubMed ID: 11908560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of antimalarials in systemic lupus erythematosus.
    Nayak V; Esdaile JM
    Lupus; 1996 Jun; 5 Suppl 1():S23-7. PubMed ID: 8803906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.